Abstract:282 Background: Albumin-bound paclitaxel has been proven to be an active agent in advanced gastric cancer, and was approved by PMDA Japan for use as a second-line treatment of advanced gastric cancer. The aim of this study was to evaluated the efficacy and safety of AS and SOX in the first-line treatment of advanced gastric cancer. Methods: Patients diagnosed with unresectable locally advanced, recurrent or metastatic human epidermal growth factor receptor type 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma were randomized (1:1) to either AS group (albumin-bound paclitaxel 260mg/m 2 d1 or 130mg/m 2 d1, 8; S-1 40 mg [BSA < 1.25 m 2 ], 50 mg [1.25 ≤ BSA < 1.50 m 2 ] and 60 mg [BSA ≥1.50 m 2 ] b.i.d. d1-14, every 3wks) or SOX group (oxaliplatin 130mg/m 2 d1; S-1 40 mg [BSA < 1.25 m 2 ], 50 mg [1.25 ≤ BSA < 1.50 m 2 ] and 60 mg [BSA ≥1.50 m 2 ] b.i.d. d1-14, every 3wks). Primary endpoint was progression-free survival (PFS), secondary endpoints included overall survival (OS), objective response rate (ORR) and safety. Results: Between March 2019 and March 2021, 96 patients were enrolled and 85 patients (AS group, n = 43; SOX group, n = 42) who received at least one dose of study drug and had at least one postbaseline efficacy evaluation were included in the final analysis. 34 (79.0%) patients in the AS group and 35 (83.3%) in the SOX group had discontinued treatment. Of these 85 patients, 78.8% had two or more organs involved, 61.2% had peritoneal dissemination, and more than 1/4 had massive ascites. Patient demographics and disease characteristics were generally balanced between arms. With median follow-up 15.4 months (95% CI, 8.8-21.9), the median PFS of AS group vs. SOX group was 9.2 vs.5.1 months (HR = 0.58 [95% CI 0.36-0.96], p = 0.034); and the median OS was 14.4 vs. 15.4 months (HR = 0.73 [95%CI 0.40-1.34], p = 0.375). Tumor response was assessable in 33 patients according to RECIST V1.1 in both cohorts, the ORR and DCR were similar in AS vs. SOX arm (ORR: 54.5% vs. 51.5%, P = 0.805; DCR: 78.8% vs. 78.8%, P = 1.000). The main grade 3 or worse treatment-related adverse events were neutropenia (30.2% vs 23.8%), Leucopenia (11.6% vs 11.9%) and peripheral sensory neuropathy (4.7% vs 7.1%) in AS and SOX group. The study was planned to be adjusted, due to the widespread use of immunotherapy in first-line treatment of gastric cancer. Conclusions: The results of this study indicated that in previously untreated patients with unresectable locally advanced, recurrent or metastatic HER2-negative gastric or GEJ adenocarcinoma, AS achieved better PFS than SOX, with an inadequate power. The toxicities were controllable and consistent with previously reported. Clinical trial information: NCT03801668.

Phase Ii Clinical Trial of S-1 Plus Nanoparticle Albumin-Bound Paclitaxel As First-Line Chemotherapy for Patients with Metastatic Gastric Cancer

Phase II Clinical Trial of S‐1 Plus Nanoparticle Albumin‐bound Paclitaxel in Untreated Patients with Metastatic Gastric Cancer

A Phase Ii Study of Biweekly Oxaliplatin and S-1(Sox) As First-Line Combination Therapy in Patients with Advanced Gastric Cancer.

A Phase Ii, Open-Label, Multicenter, Prospective Study of Paclitaxel Plus Capecitabine with Subsequent Capecitabine Maintenance Therapy As First-Line Treatment for Metastatic or Recurrent Gastric Cancer

The Multicenter, Phase Ii Prospective Study of Paclitaxel Plus Capecitabine As First-Line Chemotherapy in Advanced Gastric Carcinoma

Efficacy and Safety for Apatinib Combined with Oxaliplatin and S1 in Initially Treated Metastatic Gastric Cancer: A Single-Center Observational Study.

[A Phase II Prospective Randomized Controlled Trial of Weekly Paclitaxel Combined with S-1 or Fluorouracil for Advanced Gastric Carcinoma].

A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.

A Phase Iii Study of S-1 Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

A Retrospective Study of Adjuvant Albumin-Bound Paclitaxel Plus S-1 after D2 Gastrectomy Versus Oxaliplatin Plus S-1 in Gastric Cancer

Randomized controlled trial of S-1 and paclitaxel in the treatment of metastatic gastric cancer

Phase I/II Study of Nab-Paclitaxel Combined with S-1 As Adjuvant Chemotherapy in Diffuse Type of Stage III Gastric or Gastroesophageal Junction Adenocarcinoma

Safety Analysis of Weekly Paclitaxel Plus S-1 Versus Paclitaxel Plus 5-Fluorouracil/calcium Folinate As First-Line Therapy in Advanced Gastric Cancer: a Multicenter Open Random Phase II Trial

144O Comparison of Efficacy and Safety of Paclitaxel and Capecitabine Followed by Capecitabine As Maintenance Therapy Versus Cisplatin and Capecitabine Therapy for Advanced Gastric Cancer: a Multicentre, Randomised, Active-Controlled Phase III Study

A single centre clinical trial of docetaxel and S-1 combination therapy as first line treatment in patients with advanced or recurrent gastric cancer

A Phase II Study of Biweekly Oxaliplatin Plus S-1 Combination Chemotherapy As a First-Line Treatment for Patients with Metastatic or Advanced Gastric Cancer in China

A multicenter randomized phase III study of albumin-bound paclitaxel combined with S-1 (AS) versus oxaliplatin combined with S-1 (SOX) for first-line treatment of advanced gastric cancer (GAPSO study).

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma

Nab-paclitaxel Combined with Oxaliplatin and S-1 As Conversion Therapy for Advanced Gastric Adenocarcinoma.

A Phase II Study of Tri-weekly Low-dose Nab-paclitaxel Chemotherapy for Patients with Advanced Gastric Cancer

Comparison Of Efficacy And Safety Of Second-Line Palliative Chemotherapy With Paclitaxel Plus Raltitrexed And Paclitaxel Alone In Patients With Metastatic Gastric Adenocarcinoma: A Randomized Phase Ii Trial.